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doi:10.1Objective: This study evaluated the effectiveness of an atrial septostomy with veno-venous extracorporeal
membrane oxygenation in alleviating high afterload right ventricular dysfunction while providing respiratory
support. This technique could be applied as a bridge to lung transplantation.
Methods: Sheep (56 3 kg) underwent a clamshell thoracotomy and hemodynamic instrumentation, including
right ventricular pressure and cardiac output. Sheep with and without tricuspid insufficiency (n ¼ 5 each) were
examined. While sheep were on extracorporeal membrane oxygenation, right ventricular failure was established
by banding the pulmonary artery until cardiac output was 40% to 60% of baseline. An extracardiac atrial shunt
was created with modified vascular grafts to examine the effect of shunt flow on hemodynamics. Hemodynamic
data were thus collected at baseline, during right ventricular failure, and for 1 hour at 100% (fully open), 70%,
50%, and 30% of baseline shunt flow.
Results: Cardiac output was returned to baseline values (tricuspid insufficiency: 5.2  0.2 L/min, without
tricuspid insufficiency: 5.3  1.2 L/min) with 100% shunt flow (tricuspid insufficiency: 4.8  1.1 L/min, with-
out tricuspid insufficiency: 4.8  1.0 L/min; P ¼ .15) but remained significantly lower than baseline at 70% to
30% shunt flow. At 100% shunt flow, tricuspid insufficiency shunt flow was 1.4  0.8 L/min and without
tricuspid insufficiency shunt flow was 1.7  0.2 L/min. Right ventricular pressure was significantly elevated
over baseline values at all shunt flows (P<.001). In the group without tricuspid insufficiency, all sheep died
beginning at the 70% shunt condition, whereas all animals with tricuspid insufficiency survived the entire ex-
periment. Normal arterial blood gases were maintained under all conditions.
Conclusions: An atrial septostomy accompanied by veno-venous extracorporeal membrane oxygenation is
capable of eliminating right ventricular failure while maintaining normal arterial blood gases if sufficient shunt
flows are achieved. The presence of tricuspid insufficiency improves the efficacy of the shunt. (J Thorac Cardi-
ovasc Surg 2011;141:537-42)XSupplemental material is available online.
Pulmonary arterial hypertension has a prevalence of
approximately 15 per million in both the United States
and Europe.1,2 The prognosis of this disease is poor, with
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Ttherapy2 and 60% 2-year mortality if untreated.3 This pa-
tient population is routinely listed for lung transplantation
when refractory to conventional medical therapy. However,
because of a lack of available donor organs, a high number
of patients die on the waiting list or become unsuitable
candidates for lung transplantation. The impact of organ
shortage can be estimated by the high number of approxi-
mately 2500 patients who have died on the waiting list in
theUnited States over the last 5 years.4 Amajor contributing
factor to morbidity and mortality on the transplantation
waiting list is right ventricular (RV) failure. Therefore, RV
dysfunction is one of the most important prognostic factors
in pulmonary hypertension.5As a result, intensive efforts are
made to develop new therapeutic modalities for combined
lung and RV support. This has led to several novel drugs
and therapies entering clinical practice to facilitate bridging
patients to lung transplantation with considerable success.
To date, a poorly understood treatment option has been an
atrial septostomy.6,7 The reported success rates of atrial
septostomies for bridging patients to lung transplantation
range from 30% to 40%.6 These low success rates can berdiovascular Surgery c Volume 141, Number 2 537
Abbreviations and Acronyms
CO ¼ cardiac output
ØTI ¼ without tricuspid insufficiency
QShunt ¼ shunt flow rate
RAP ¼ right atrial pressure
RV ¼ right ventricular
RVP ¼ right ventricular pressure
TI ¼ tricuspid insufficiency
VV ECMO ¼ veno-venous extracorporeal
membrane oxygenation
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Xexplained by an oftentimes unpredictable decrease in arte-
rial oxygen saturation. Therefore, patients with severe gas
exchange physiology are not suitable candidates for this ap-
proach, which has limited the application of atrial septosto-
mies as a bridge to transplantation. These patients would
then require extracorporeal blood oxygenation with veno-
venous extracorporeal membrane oxygenation (VV
ECMO). Reports on the use of ECMO alone as a bridge to
lung transplantation are isolated, and the outcomes remain
mixed because of the low sample size of patients. However,
recentmajor technical advances in ECMOenable patients to
be supported with relative safety for several weeks up to
months, facilitating even extubation until donor organs be-
come available.8,9 Several large series now report
improved survival for patients with acute severe
respiratory failure treated with VV ECMO.10,11 The
results obtained by the CESAR-Trial indicate a possible ad-
vantage for ECMO over conventional treatment for revers-
ible severe pulmonary failure.12,13 Therefore, the use of
VV ECMO for severe, refractory lung failure can be
expected to increase in the near future.
To date, there is no published evidence to support the ef-
fectiveness of an atrial septostomy and VV ECMO at treat-
ing concomitant respiratory and RV failure. This study was
designed to evaluate the feasibility of this new approach as
a potential novel bridge to lung transplantation and the he-
modynamic factors affecting its success. This study uses an
extra-anatomic interatrial shunt in a large animal model to
assess the effect of the shunt flow rate (QShunt) and tricuspid
insufficiency (TI) on RV function and arterial blood gases.
MATERIALS AND METHODS
All animals received care compliant with the ‘‘Principles of Laboratory
Animal Care’’ formulated by the National Society for Medical Research
and the ‘‘Guide for the Care and Use of Laboratory Animals’’ prepared
by the National Academy of Sciences and published by the National
Institutes of Health. The study was approved by the University ofMichigan
Committee on Use and Care of Animals.
Surgical Instrumentation
Adult male sheep (56  3 kg) were anesthetized using a standard pro-
tocol as previously described and used by our laboratory.14 The ventilator538 The Journal of Thoracic and Cardiovascular Surg(Narkomed 600; North American Draeger, Telford, Pa) was set initially at
a tidal volume of 10 mL/kg and a frequency of 12 to 15 breaths/min. It was
adjusted as needed to maintain the arterial PCO2 between 35 and 45 mmHg
with a peak inspiratory pressure less than 30 cm H2O. Arterial and venous
accesses were established by carotid and jugular catheterization using PVC
tubing (Abbott Critical Care Systems, North Chicago, Ill). The arterial
catheter was connected to a fluid coupled pressure transducer (Abbot Crit-
ical Care Systems) to monitor arterial pressure, which was displayed con-
tinuously (Marquette Electronics, Milwaukee, Wis).
A clamshell thoracotomy was performed, entering the chest cavity
through the fourth intercostal space. A 60 mg dose of intravenous ketorolac
(Hospira, Inc, Lake Forest, Ill) was given before the transverse sternotomy.
After opening the pericardium, a 16F angiocatheter (Becton, Dickinson In-
fusion Therapy Systems Inc, Sandy, Utah) was inserted into the right atrium
and connected to a fluid-coupled pressure transducer to measure right atrial
pressure (RAP). A 6F micromanometer tipped pressure probe (Millar
Instruments, Inc, Houston, Tex) was inserted into the conus region of the
RV free wall to measure RV pressure (RVP). An ultrasonic perivascular
flow probe (T206 Flowmeter; Transonic Systems, Ithaca, NY) was placed
around the ascending aorta to measure continuous cardiac output (CO).
Heparin (100 U/kg, intravenously; Baxter Healthcare Corporation, Deer-
field, Ill) was administered to maintain activated clotting times greater
than 400 seconds.
Right to left interatrial shunting was realized with a custom-made
extracardial shunt consisting of 40-cm 31F long tubing (Fisher Scientific
Company, Pittsburgh, Pa) and 2 right-angled metal 31F cannulas on both
ends (Figure E1). The extracardial shunt was introduced through purse-
string sutures into the right and left atrial appendages. To measure the
flow rate through the interatrial shunt, QShunt, an ultrasonic tubing flow
probe was attached (Transonic Systems). In one group of sheep (n ¼ 5),
TI was created by introducing a custom-made fenestrated 16F cannula
through the right atrium into the right ventricle. After introducing the can-
nula, it was secured in place. TI was verified by significant pulsatile back-
flow in the jugular vein (Cannon-V waves). In another group (n ¼ 5), TI
was not created (ØTI).
Cardiopulmonary Bypass and Extracorporeal
Membrane Oxygenation
The ECMO circuit consisted of a centrifugal pump (Biomedicus 520 D;
Medtronic Minneapolis, Minn), heater unit (ECMO-Temp, Zimmer, Do-
ver, OH), oxygenator (Capiox SX; Terumo, Ann Arbor, Mich), and 30F Ty-
gon tubing. The circuit was primed with 800 mL Lactated Ringer solution
mixed with 50 mL of bicarbonate solution. ECMO was established with
standard techniques for VV ECMO by drainage from the iliac vein with
an 18F cannula (TenderFlow; Terumo Cardiovascular, Ann Arbor, Mich)
and reinfusion into the superior vena cava with an 18F straight cannula in-
troduced through the right jugular vein (L-Series; Terumo Cardiovascular).
Before initiating ECMO, 500 mg of methylprednisolone (0.5 g intrave-
nously; Pfizer, New York, NY) was administered to reduce the inflamma-
tory response to the foreign surfaces of the circuit. ECMO flow was kept
between 2.5 and 3.5 L/min, and O2 at 100% FIO2 was delivered at a flow
rate of 2 to 6 L/min based on arterial blood gases. On initiation of
ECMO, the ventilator rate was changed to 8 breaths/min. Low doses of nor-
epinephrine (Sicor, Irvine, Calif; 0.05–0.1 mg/min/kg intravenously) were
administered to keep mean arterial pressure greater than 50 mm Hg before
the establishment of ECMO to reduce the vasodilatory effects of the inflam-
matory response.
Experimental Procedure and Data Collection
After initiating ECMO, 10 minutes were allowed for equilibration and
a baseline data set was acquired. A complete data set consisted of RAP,
RVP, pulmonary artery pressure, CO, and QShunt. At each data acquisition
point, all parameters were collected manually using Excel (Microsoft, Red-
mond,Wash). RVPwas also acquired digitally at 250Hz using Labview 7.0ery c February 2011
FIGURE 1. CO at each shunt condition in TI and ØTI groups. CO, Car-
diac output; RV, right ventricular; TI, tricuspid insufficiency; ØTI, without
tricuspid insufficiency.
Camboni et al Cardiothoracic Transplantation(National Instruments, Austin, Tex) and stored on a personal computer
(Dell Computer Corporation, Round Rock, Tex).
After collection of baseline data, RV failure was created by progres-
sively banding the pulmonary artery. RV failure was defined as a 40% to
60% decrease of CO from baseline and a 2-fold increase in RAP. After
10 minutes of RV failure, a complete data set was taken. The atrial shunt
was then opened. Flow was left fully open (100%) for 1 hour followed
by 1 hour each at 70%, 50%, and 30%. This flowwas titrated using a Hoff-
man clamp on the shunt. At each shunt condition, data were acquired after
1 hour, except arterial, right, and left atrial blood gases, which were col-
lected every 20 to 30 minutes. At the end of the experiment, sheep were eu-
thanized using 90 to 150 mg/kg of pentobarbital (Fatal-Plus; Vortech
Pharmaceuticals, Dearborn, Mich).
Statistical Evaluation
All data are presented as mean  standard deviation collected in each
experimental condition. All manually collected data from survivors and
nonsurvivors were compared using the mixed-model analysis within
SPSS 17 (SPSS Inc, Chicago, Ill). On comparison of the hemodynamic
variables, the experiment number was the subject variable and the shunt
flow condition and TI group were the independent variables. Multiple com-
parisons confidence intervals were adjusted according to the Bonferroni
method to minimize type I errors. To compare the effect of TI group on he-
modynamics or gas exchange, the subject and dependent variables remain
the same, but baseline and RV failure data were excluded to focus on the
effect of TI during ECMO and interatrial support.RESULTS
Survival
Right to left atrial shunting successfully eliminated com-
plete RV failure under all shunt conditions when TI was
present. On the other hand, animals with a competent tricus-
pid valve (ØTI) experienced complete RV failure and death.
One animal died at the end of the 70% shunt flow period;
another animal died at 50% shunt flow; 2 animals died dur-
ing the 30% shunt flow period; and the remaining last ØTI
animal died immediately after completion of the 30%
period of 60 minutes.FIGURE 2. Mean RVP at each shunt condition in TI and ØTI groups. RV,
Right ventricular; TI, tricuspid insufficiency; RVP, right ventricular
pressure.
T
XHemodynamics
Baseline CO was similar in both groups with 5.2 0.2 L/
min in the TI group and 5.3  1.2 L/min in the ØTI group
(Figure 1). After RV failure was established, CO decreased
to 2.2  1.1 L/min in the TI group and 2.3  0.4 L/min in
the ØTI group (P<1010). With 100% shunt flow, QShunt¼
1.4 0.8 L/min in the TI group and 1.7 0.2 L/min in ØTI
group (Figure E2), and CO was not significantly different
than baseline in both groups (TI: 4.8  1.0 L/min; ØTI:
4.8  1.1 L/min; P ¼ .74). Thereafter, CO diminished sig-
nificantly with decreasing shunt flow. CO became signifi-
cantly lower at 70% compared with baseline in both
groups (TI: 4.3  1.04 L/min; ØTI: 4.5  0.8 L/min;
P<.01) and was significantly lower than baseline at 50%
and 30% (P<104 and P<.001). There was no significant
difference between TI and ØTI groups (P ¼ .60).
Mean RVP increased significantly from 12.7  1.2 mm
Hg at baseline to 24  2 mm Hg at the imposed RV failureThe Journal of Thoracic and Cacondition in the TI group and from 11.3  1.5 mm Hg to
24  7 mm Hg in the ØTI group at the same conditions
(Figure 2; P< 107). Mean RVP at full shunt flow (TI:
25  7 mm Hg; ØTI: 23  10 mm Hg) was significantly
higher than at baseline in both groups (P< .01) and re-
mained significantly elevated at all shunt flows (P<.001–
.01). Typical examples of RVP tracings are shown in
Figure E3. There was no significant difference between TI
and ØTI groups (P ¼ .77).
Results for mean pulmonary artery pressure followed sim-
ilar trends as mean RVP (Table 1), with significantly elevated
values at the RV failure condition (P<.001) and all shunt
flows (P<.001–.05) with the exception of 50%, which ap-
proaches significance (P¼ .08).Once again, therewas no sig-
nificant difference between TI and ØTI groups (P ¼ .48).
Mean RAP was also significantly elevated at the RV failure
condition (P< 107) and at all shunt flows (P<.001–.05).
However, unlike mean RVP, mean RAP decreased with in-
creasing shunt flow, suggesting improved right to left blood
flows. In the TI group, this effect is less pronounced, withrdiovascular Surgery c Volume 141, Number 2 539
TABLE 1. Pulmonary artery, radial artery, and left artery pressures (mm Hg)
Condition
BL Right ventricular failure 100% shunt 70% shunt 50% shunt 30% shunt
Mean PAP
TI 15.4  2.3 26.6  4.3 26.8  5.1 26.5  5.2 24.9  6.4 30.9  13.3
ØTI 12.6  5.8 25.4  5.7 25.2  6.9 23.1  7.7 21.8  6.3 24.0  6.9
Mean RAP
TI 3.6  2.5 7.6  2.7 7.1  2.2 7.3  2.1 8.7  1.8 8.8  1.5
ØTI 4.4  1.9 11.2  2.7 7.6  1.8 8.9  3.7 8.3  4.4 10.3  5.0
BL, Baseline; PAP, pulmonary artery pressure; TI, tricuspid insufficiency; ØTI, without tricuspid insufficiency; RAP, right atrial pressure.
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XRAP¼ 7.6 2.7mmHgat theRV failure condition and 7.1
2.2 mm Hg at 100% QShunt. In the ØTI group, the effect is
much larger, decreasing from 11.2  2.7 mm Hg to 7.6 
1.8 mm Hg at the same conditions. However, there was no
difference between the TI and ØTI groups (P ¼ .67).
Gas Exchange
VV ECMO maintained mean oxygen saturation greater
than 99% on average with an overall average PO2 of
243  102 mm Hg (minimum, 81 mm Hg) and an overall
average PCO2 of 38  6 mm Hg (minimum, 18 mm Hg;
maximum, 50 mm Hg) in the TI group (Figure 3). Similar
gas exchange was evaluated in the ØTI group (Figure 4)
with a mean oxygen saturation greater than 99%, PO2 of
120  68 mm Hg (minimum, 55 mm Hg), and PCO2 of
35  5 mm Hg (minimum, 24 mm Hg; maximum, 44 mm
Hg). The PO2 and PCO2 were significantly different between
the TI and ØTI groups (P<.01 for both). Mean RA PO2 av-
eraged 188 84 mmHg across both TI groups with a mean
PCO2 of 39 10 mm Hg. Similarly, mean left atrial PO2 was
211  64 mm Hg, and the mean PCO2 was 35  5 mm Hg.
Disconnecting O2 supply to the oxygenator at 100% flow to
the shunt resulted in a decrease in arterial PO2 to 58 4 mm
Hg and an increase in arterial PCO2 to 58  16 mm Hg.FIGURE 3. Arterial blood PO2 and PCO2 for the TI group. RV, Right
ventricular.
540 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
The surgical exclusion of the failing right ventricle is re-
ported to be an effective management in patients with post-
operative refractory RV dysfunction.15 Therefore, volume
unloading the failing right ventricle has proven successful.
In the setting of severe primary pulmonary hypertension,
early experimental studies in the mid-1960s and clinical ob-
servations in the mid-1980s have suggested that an intera-
trial shunt may be beneficial for the treatment of RV
failure.16,17 The atrial septal defect allows right to left
shunting and a resultant increase in systemic CO. This
leads to an increase in systemic oxygen delivery despite
a decrease in systemic arterial saturation.18-20 Thus, atrial
septostomies are occasionally performed either as a sole
treatment for refractory RV failure or to bridge patients to
lung transplantation.6,7 However, patients with severe gas
exchange deficiency are not suitable candidates for this
approach. Therefore, our hypothesis was that the
combination of an atrial septostomy with extracorporeal
gas exchange by VV ECMO could be a successful
approach to support these patients.
Various pulmonary devices have entered clinical practice
to treat respiratory failure, but only a few devices and man-
agement concepts also treat ventricular failure. Of these, theFIGURE 4. Arterial blood PO2 and PCO2 for the ØTI group.
ery c February 2011
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Xparacorporeal artificial lung is a promising innovation for
pulmonary and ventricular support. This artificial lung is at-
tached between the pulmonary artery and the left atrium,
thereby improving gas exchange while reducing RV after-
load.14,21,22 However, this approach requires an invasive
thoracotomy in critically ill patients, exposing them to the
risk of anesthesia and major surgery. In addition, the
artificial lung attachment results in technically more
difficult lung transplantation because of induced native
lung and heart adhesions.
In contrast, an atrial septostomy is performed percutane-
ously, oftentimes requiring only sedation rather than gen-
eral anesthesia. This diminishes the risk associated with
anesthesia and technically difficult major thoracic surgery.7
Furthermore, ECMO does not necessarily require sedation,
and it is perfectly feasible in an alert, extubated, spontane-
ously breathing patient, the ideal transplant candidate.23
Novel technical achievements, such as the 2009 Food and
Drug Administration-approved double-lumen cannula for
veno-venous gas exchange, facilitate the use of ECMO as
a percutaneously introduced portable paracorporeal
lung.24 This new cannula for adult ECMO support is intro-
duced into the jugular vein draining from both vena cavae
and reinfusing into the right atrium directly through the tri-
cuspid valve into the right ventricle. It may be that this novel
cannula will improve flows of oxygenated blood to the left
atrium in the setting of a combined ECMO and atrial septal
defect support. On the other hand, ECMO causes larger ac-
tivation of blood components than paracorporeal artificial
lungs because of its large circuit and mechanical pump.
Thus, the resulting systemic inflammatory response and
thrombogenicity are greater.
The study presented was designed to examine the effec-
tiveness of right to left atrial shunting with VV ECMO at
treating high-afterload RV failure. Our results indicate
that right to left atrial shunting is capable of treating acute
severe RV failure, here defined by a 40% to 60% decrease
in CO. This degree of RV failure would otherwise be fatal.
The necessary amount of right to left atrial shunt flow
needed to treat this degree of acute RV failure seems to
be as low as approximately 8% of baseline CO to avoid
RV failure when TI is present but ideally greater than
20% to maintain baseline CO. However, the animals of
this study did not have the typical hypertrophic ventricle
present in patients with chronic lung disease. The required
shunt fraction in a hypertrophied RV may be lower because
the RV is already adapted to high afterloads.
All animals with TI survived the entire experiment, but
sheep without TI required a QShunt greater than 13% of
baseline CO to avoid complete RV failure and death. The
insufficient tricuspid valve likely acts as a ‘‘pop off valve,’’
allowing a slightly greater blood flow through the atrial sep-
tal defect (Figure E2) in the TI group. This result is not fully
explained by the hemodynamic data from this study, be-The Journal of Thoracic and Cacause statistical comparison did not find significant differ-
ences between the TI and ØTI groups for all measured
parameters. The cause of this is that ØTI animals with
poorer hemodynamics died earlier in the course of the ex-
periment, leaving only animals with better RV function.
Thus, small differences in shunt flow between the groups
at 100% QShunt disappeared at lower shunt flows as weaker
members of the ØTI group died. Finally, because stable he-
modynamics were maintained regardless of the presence of
TI, a combined VV ECMO and interatrial shunt support
might be applicable for both group of patients.
The shuntwas able to unload the right ventricle sufficiently
to allow increased CO but not sufficiently to reduce RVP. As
the shunt resistance decreased, the overall resistance of the
right ventricle to left atrial flow pathway was reduced. This
led to greater volume unloading of the RVand a small, statis-
tically insignificant decrease in RAP. There were no RV vol-
ume measurements in this study, but it is likely that RVend-
diastolic volume was also reduced. Such a reduction leads to
a reduction in the ventricular work necessary to pressurize
blood before ejection, and this work was likely used instead
to generatemore productive strokework. Thus, CO increased
with increasing shunt flow, and as a result, mean RVP re-
mained elevated despite the volume unloading. Because
CO was returned to a normal value at 100% QShunt, further
increases in shunt flow would likely have no effect on CO
and thus result in lower RVP. This may be possible with
a less resistant atrial septal defect created via septostomy.
These results are comparable to a similar study con-
ducted by Zierer and collagues.25 In that study, low versus
high atrial shunt flow was compared in dogs with chronic
right heart failure after 3 to 4 months of progressive pulmo-
nary artery banding. The role of the tricuspid valve in atrial
shunting was not considered. The authors reported that CO
increased beyond baseline with a shunt flow equal to 15%
of CO. On the other hand, a shunt flow of 29% of CO did
not increase CO beyond baseline. The authors concluded
that high flows seem to exceed an ideal shunt fraction. In
comparison, our results indicate that a shunt fraction be-
tween 20% and 30% of baseline CO is capable of treating
RV failure, and a shunt fraction less than 20% of baseline
CO results in decreased CO. The reason for this discrepancy
is explained by a different study design. The animals of the
present study had normal hearts without RV hypertrophy
and a more severe, acute RV failure, perhaps diminishing
the CO increase at small shunt flows, but also provided
gas exchange, allowing better function at high shunt flows.
Study Limitations
The present study was designed to examine a bridge to
transplantation for patients with chronic pulmonary hyper-
tension caused predominantly from pathologies in the
peripheral vascular tree and consecutive RV failure. How-
ever, our study more closely resembles acute RV failurerdiovascular Surgery c Volume 141, Number 2 541
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Xsimilar to a severe pulmonary embolism. Despite this, the
proposed bridge is designed for critically ill patients who
have had an acute-on-chronic event (eg, acute pneumonia)
leading to a severe deterioration of pulmonary hypertension
and RV failure. The presented animal model simulates this
clinical scenario for themost part. Nonetheless, improved re-
sults may be achieved using animals with chronic pulmonary
hypertension and a partially compensated right ventricle.
CONCLUSIONS
Right to left atrial shunting of oxygenated blood with VV
ECMO is capable of eliminating acute, severe, normally
lethal RV failure while maintaining normal arterial blood
gases. The presence of TI seems to improve RV function
during application of this potentially novel technique to
bridge patients to lung transplantation.
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FIGURE E1. Right to left atrial shunting was simulated with a custom-
made 31F extracardiac shunt introduced into the atrial appendages.
FIGURE E2. QShunt at each shunt condition in TI and ØTI groups. RV,
Right ventricular; TI, tricuspid insufficiency; ØTI, without tricuspid insuf-
ficiency; QShunt, shunt flow rate.
FIGURE E3. Typical examples of RVP tracings at each condition. RV,
Right ventricular.
Camboni et al Cardiothoracic Transplantation
The Journal of Thoracic and Cardiovascular Surgery c Volume 141, Number 2 542.e1
T
X
